lungcancersymptomsx.com
New Study Identifies Drug to Boost Lung Cancer Survival Rates
A new study has found that a newly approved drug for leading form of cancer, lung cancer works to improve patient survival rate. The immunotherapy drug is called Tecentriq or atezolizumab. It was approved earlier by US Food and Drug Administration to treat newly diagnosed non-small cell lung cancer (NSCLC). NSCLC comprises up to 85%